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The classical randomized controlled clinical trial is designed to prove superiority of an
investigational therapy over an established therapy or placebo (here referred to as ‘‘superiority
trial’’). Although the randomized controlled superiority trial has its well-grounded role,
clinical trials of non-inferiority are equally important in the advance of medical science. Non-
inferiority trials test whether a new intervention is as good as a standard treatment with
respect to curing the illness (e.g., overall survival) while offering other beneﬁts over the
standard therapy, such as lower toxicity, better side-effect proﬁle, improved ease of admin-
istration, or reduced costs. The evaluation of non-inferiority is critical in many settings. In
surgical oncology, for instance, treatments often combine advantages (e.g., survival beneﬁt)
with disadvantages (e.g., high post-operative morbidity due to extensive surgery, considerable
toxic effects of an aggressive chemotherapy regimen). The various aspects of different thera-
peutic strategies may make a treatment decision difﬁcult, requiring a non-inferiority trial to
quantify risks and beneﬁts. However, despite their great importance in clinical cancer research,
the concept, design, and objectives of non-inferiority trials remain poorly understood in the
surgical community. The goal of this review is to discuss the principles, strengths, and chal-
lenges of non-inferiority trials and introduce this highly relevant topic to the surgical reader,
using examples from the ﬁeld of surgical oncology.
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Biocreep.
Traditional clinical trials compare a new treatment
with a placebo or with the standard treatment with
the aim of demonstrating superiority of the new
treatment (referred to as ‘‘superiority trials’’). Eﬃ-
cacy is most reliably demonstrated in this setting if a
statistically signiﬁcant diﬀerence is found. However,
superiority trials are not always best suited to answer
the clinical research question at hand.
For instance, in surgical oncology, clinical trials
frequently have several endpoints. One endpoint,
often overall survival, is designated as the primary
endpoint. However, there are other relevant out-
comes such as post-operative quality of life, short-
and long-term morbidity, cosmesis, and costs, all of
which are important for both patients and health care
providers. For instance, a small decrease in overall
survival may be justiﬁed—or even desired by pa-
tients—if there is a corresponding large gain in post-
operative quality of life. In this setting, a non-inferi-
ority trial may be the most appropriate study design.
Non-inferiority trials are performed to assess
whether a new, investigational treatment or surgical
procedure has equivalent (non-inferior) eﬃcacy in
treating the illness (e.g., similar overall survival) to an
established treatment while oﬀering other, relevant
advantages. In surgical oncology, we are challenged
by the rapid pace of change in surgical techniques.
These new surgical techniques may be less invasive,
more convenient and faster to perform, less expen-
sive, or associated with an improved post-operative
quality of life, compared to the existing procedure.
However, prior to abandoning the standard tech-
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nique, it is essential to assess whether the new pro-
cedure has equivalent (or non-inferior) eﬃcacy
regarding overall survival.
Moreover, if an eﬀective therapy already exists,
performing a placebo-controlled randomized clinical
trial may pose ethical questions.1–5 In this setting, it is
appropriate either to conduct a superiority trial
comparing a new treatment to a standard treatment,
or to design a non-inferiority trial to compare a new
therapeutic approach to an established standard
therapy, assuming the new therapy to be equivalent
(non-inferior) to the standard therapy with respect to
efﬁcacy while having other signiﬁcant advantages.
STATISTICS IN THE DESIGN OF
NON-INFERIORITY TRIALS
Non-Inferiority Margin (‘‘delta’’, d)
From a statistical point of view, proving equiva-
lence is like squaring the circle: it is impossible.3,6–8 If
one were to try to prove ‘‘equivalence’’, the sample
sizes for such a trial would be inﬁnitely large.9 Thus,
the investigators must specify a non-inferiority mar-
gin (‘‘equivalence margin’’ or ‘‘delta’’, d).6 This
margin states how similar the performance of a new
intervention must be relative to the standard treat-
ment to be considered ‘‘non-inferior’’ or ‘‘equiva-
lent’’. Hence, delta can be described as the chosen
deﬁnition of inferiority in a non-inferiority trial. It is
critically important that the non-inferiority margin be
speciﬁed prior to the initiation of the study (a priori
hypothesis).10 The choice of delta will be the chief
determinant of the sample size.11 The sample size is
proportional to 1/delta2: the smaller delta, the larger
the sample size (and vice versa).
Choosing the appropriate non-inferiority margin
for a given study is a challenging but essential task.12
The ﬁrst step is to estimate the expected effect of the
standard therapy. Some investigators have suggested
that the non-inferiority margin should be smaller
than the expected effect size of the standard treat-
ment to ensure that the investigational treatment has
at least some efﬁcacy.2,10,12 However, in many con-
texts this premise is not sufﬁcient and investigators
require a greater percentage of efﬁcacy of the inves-
tigational treatment compared to the standard one.
The choice of a non-inferiority margin usually de-
pends on all of the following factors: (a) known effect
of standard therapy over placebo, (b) severity of the
disease under investigation, (c) toxicity concerns, and
(d) primary study endpoint.13 Therefore, choosing
the appropriate delta represents a difﬁcult task that
requires extensive knowledge and input from both
statisticians and clinicians.10,14 The non-inferiority or
equivalence margin may reﬂect the least clinically
relevant difference. A new therapy may then be ac-
cepted in a non-inferiority trial if the difference be-
tween investigational and standard treatment is
smaller than delta. This precludes the possibility that
there exists a clinically relevant difference between the
two treatments.15 Ideally, a smaller delta should be
selected if a more severe condition is being studied
and/or if mortality is the primary endpoint. However,
there is no true consensus for selection of non-infe-
riority margins9, which may vary even among trials in
similar therapeutic areas.
Research Hypotheses in Non-Inferiority Trials
Traditional randomized clinical trials aim to prove
a clinically relevant diﬀerence between standard and
investigational therapy (alternative hypothesis, Ha),
while the null hypothesis (H0) states that no diﬀer-
ence between the treatments under investigation ex-
ists.19 Importantly, a traditional superiority trial
failing to reject the null hypothesis of no difference
between treatments does not demonstrate equiva-
lence of the treatments.
In the design of a non-inferiority trial, the null
hypothesis (H0) is that the treatment in arm 2
(investigational treatment) is worse than the treat-
ment in arm 1 (standard treatment) by a diﬀerence
equal to or greater than the non-inferiority margin
(Table 1).20 If, however, the difference between the
investigational and the standard treatment is smaller
than the pre-speciﬁed equivalence margin (delta, d) or
if the investigational treatment is superior to the
standard treatment, the null hypothesis (H0) can be
rejected, providing evidence supporting the adoption
of the new treatment (Table 1).
Some statisticians and researchers diﬀerentiate
between ‘‘non-inferiority’’ and ‘‘equivalence trial’’
designs.16,17,18 The former refers to a one-sided trial
design (difference in outcome < delta), whereas the
latter has a two-sided study design (difference in
outcome between )delta and +delta). Because of
their intrinsic similarities in design and reporting and
for the sake of simplicity, this educational review will
not differentiate between non-inferiority and equiv-
alence trials.
Type I and Type II Error
A type I error (synonym: alpha) is a false-positive
result21 regardless of the type of study. In a non-
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inferiority trial a type I error is to falsely conclude that
the new therapy is equivalent (= non-inferior) to or
even superior than the standard therapy when this is
not the case. Conversely, a type II error (beta, false-
negative result)21 in a non-inferiority trial is to falsely
conclude that the new therapy is not equivalent
(= inferior) to the standard therapy when both
treatments are in fact equally efﬁcient (Table 2).6,19 In
a non-inferiority trial, committing a type I error
(obtaining a false-positive result) puts future patients
at risk of having a poorer outcome (e.g., overall sur-
vival) as a result of the use of the new therapy whi-
ch—in reality—is inferior to the standard treatment.22
The risk of obtaining a false-positive result can be
minimized either by setting the type I error probability
below the standard of 0.05 (e.g., a = 0.01) or by
choosing a very small non-inferiority margin (delta).
Such precautionary methods may, however, lead to
very large sample sizes6,11,19,23 potentially associated
with enormous costs and efforts and thereby threat-
ening the feasibility of the study.
If a false-negative result (type II error) occurs in a
non-inferiority trial, future patients will not beneﬁt
from a new therapeutic approach with equal eﬃcacy
but other signiﬁcant advantages (e.g., less invasive
surgical procedure, less toxic chemotherapy regimen).
The risk of obtaining false negative result can be
minimized either by setting the type II error proba-
bility below the standard of 0.10–0.20 (e.g.,
b = 0.05) or by choosing a larger non-inferiority
margin.
Importantly, although the chosen non-inferiority
margin inﬂuences the probability of committing type
I and II errors, the selected delta must be set based on
meaningful clinical criteria, and should not be driven
by statistical constraints.
Sample Size
Sample size computations are crucial in the design
of clinical trials and help to estimate the needed
number of subjects for a given study. The importance
for appropriate sample size computations is obvious:
if the sample size is too large, resources will be wasted
and the study may even be ethically questionable.
Conversely, if the sample size is too small, the study
will be underpowered thereby hindering researchers
from drawing meaningful conclusions.12,19,24
In a conventional superiority trial, the power of a
study is the probability of ﬁnding a statistically sig-
niﬁcant result for a speciﬁed true diﬀerence in the
overall population.19,21 An underpowered study due
to a too small sample size may result in a statistically
non-signiﬁcant difference (a false-negative result),
even if a clinically relevant difference exists, and
hence may lead to erroneous conclusions.19,24,25
In a non-inferiority trial, the power of a study is the
probability of ﬁnding equivalence (non-inferiority)
between standard and investigational treatment if in
fact the two therapies are equivalent in the overall
population. Power is related to the alternative
hypothesis, i.e., generally ‘‘no diﬀerence’’ in a non-
inferiority trial. Furthermore, power is associated
with the probability of committing a type II error (b,
false-negative result): power = 1 ) b. The higher the
power, the lower the risk of committing a type II
error. Conversely, an underpowered study will in-
crease the risk of committing a type II error and may
bias the study toward the null hypothesis (a false-
negative result), even if the two treatments are
equivalent.3,26 It is therefore absolutely critical to
perform sample size computations early in the pro-
cess of designing the study. Only thoroughly per-
formed sample size estimates and consecutively
TABLE 1. Research hypotheses in non-inferiority and
superiority clinical trials
Non-inferiority trial Conventional superiority trial
H0: Es ) Ei ‡ delta
(inferiority)
H0: Es ‡ Ei, or H0: Es ) Ei ‡ 0
Ha: Es ) Ei < delta
(non-inferiority)
Ha: Es < Ei, or Ha: Es ) Ei < 0
Es, efﬁcacy of standard treatment; Ei, efﬁcacy of investigational
treatment; delta: non-inferiority margin.
The null hypothesis (H0) of a non-inferiority trial states that the
absolute diﬀerence between standard and investigational treatment
exceeds the non-inferiority margin (delta). The alternative
hypothesis (Ha) states that the absolute diﬀerence is smaller than
delta.
TABLE 2. Type I and II errors
Non-inferiority trial Conventional superiority trial
Type I error = a
(false positive)
Type I error = a (false positive)
ﬁ False conclusion
that ES ) Ei < delta
ﬁ False conclusion that ES < Ei, or
ﬁ False conclusion that Es ) Ei < 0
Type II error = b
(false negative)
Type II error = b (false negative)
ﬁ False conclusion
that ES ) Ei ‡ delta
ﬁ False conclusion that ES ‡ Ei, or
ﬁ False conclusion that Es ) Ei ‡ 0
Es, efﬁcacy of standard treatment; Ei, efﬁcacy of investigational
treatment; delta: non-inferiority margin.
A type I error (false-positive result) in a non-inferiority trial is to
falsely conclude that the new therapy is equivalent to, or superior
than the standard therapy. A type II error (false-negative result) in
a non-inferiority trial is to falsely conclude that the new therapy is
inferior to the standard therapy.
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resulting adequately large patient samples will pre-
vent from obtaining false-negative ﬁndings, and
hence from potentially hindering patients of the
beneﬁts of the investigational treatment.
The sample size in a non-inferiority trial depends,
among other parameters, on the accepted rate of
false-positive results (chosen type I error, alpha),
the accepted rate of false-negative results (chosen
type II error, beta), and the selected non-inferiority
margin (delta). Sample size, alpha, beta, and delta
are the four important parameters in the design of
a non-inferiority trial. Investigators can specify only
three of these parameters and subsequently deter-
mine the fourth. Generally, a margin of non-infe-
riority (delta) is ﬁrst determined, which must be
based on the expected eﬃcacy of both standard and
investigational treatments. The accepted rate of
false-positivity (alpha) is then chosen as well as the
power of the study (complementary to beta). Based
on these parameters an adequate sample size can be
calculated.
CHALLENGES AND CAVEATS IN THE
CONDUCT AND INTERPRETATION OF
NON-INFERIORITY TRIALS
Assay Sensitivity
Assay sensitivity refers to the ability of a study to
diﬀerentiate between active and inactive treatments.27
In a superiority trial, which aims to prove superiority
of an investigational treatment over an established
treatment or placebo, there is compelling evidence of
the efﬁcacy of this treatment if a statistically signiﬁ-
cant difference is found.15 In this setting, no infor-
mation from outside of this trial is needed to
conclude efﬁcacy.27 Conversely, a non-inferiority trial
may not address the efﬁcacy of the treatments under
investigation, but it does assess whether any differ-
ence in efﬁcacy between the treatments is signiﬁcantly
less than the chosen delta (equivalence or non-infe-
riority margin). Hence, the investigator must assume
that the standard treatment was in fact effective in the
performed study to conclude efﬁcacy of the investi-
gational treatment.15 This assumption of efﬁcacy can
be made if the standard treatment consistently dem-
onstrated efﬁcacy for the condition in question in
previous placebo-controlled studies.2,12,15,27 Assay
sensitivity represents a critical issue in non-inferiority
trials and efﬁcacy of the investigational treatment
cannot be demonstrated if the assumption of the as-
say sensitivity is impossible.11,27
The challenge of assay sensitivity could be removed
if a three-arm (standard treatment vs. investigational
treatment vs. placebo) non-inferiority trial were de-
signed.11 The alternative hypothesis would then be
that the new, investigational treatment is non-inferior
to the standard treatment but performs signiﬁcantly
better than placebo. However, the use of surgical
placebos (sham surgery) is highly controversial and
thus, surgical placebos are rarely used.25
Improper Study Design, Conduct, or Interpretation
Improper study design and conduct (e.g., non-
compliance of patients, drop-outs, inclusion of ineli-
gible patients, etc.) is likely to decrease an existing
diﬀerence between two treatments.12,23 In a tradi-
tional superiority trial, investigators are keen in
avoiding such ‘‘sloppiness’’,3 in order to preclude the
possible blurring of an existing difference. Further-
more, a failure to ﬁnd a statistically signiﬁcant dif-
ference between standard and investigational therapy
might be due to an underpowered study design, to the
occurrence of too few events, or to an imprecise
measurement of the outcome (large variability).19,24,26
Conversely, in a non-inferiority trial, improper
study design or conduct may bias the results towards a
ﬁnding of equivalence (the alternative hypothesis).23
Non-inferiority trials are particularly sensitive to
protocol deviations. For instance, deviations from the
inclusion criteria, from the intended treatment (cross-
over), or from the treatment schedule may result in
smaller differences between standard and investiga-
tional treatment and hence make a conclusion of non-
inferiority more likely. Thus, the investigators may
wrongly conclude that the new investigational treat-
ment is non-inferior to the standard treatment (false-
positive result), whereas in fact, the standard treat-
ment is superior with respect to efﬁcacy compared
with the new treatment. Future patients who undergo
the new treatment may be at risk of having a poorer
outcome due to this false conclusion. Thus, it is crit-
ically important that non-inferiority trials be per-
formed with greatest attention to methodological
rigor and study conduct.12 Indeed, the existent liter-
ature documents that only a few trials concluding no
difference between two treatments under investigation
were actually adequately designed and conducted as
non-inferiority trials with sufﬁcient power. Greene
et al.9 recently reviewed 88 published controlled clin-
ical trials and only found 23% of studies that reported
equivalence actually setting an equivalence boundary
and conﬁrming it statistically. In addition, only
33% of reports calculated a sample size necessary to
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conﬁrm their results prior to conducting the trial. The
authors suggest that many investigators conclude
similarity based upon inappropriate statistical tests or
inadequate sample sizes, possibly leading to unreliable
and potentially dangerous information being em-
ployed in clinical practice.9
‘‘Intention-to-Treat’’ Versus ‘‘Per Protocol’’ Analysis
Intention-to-treat represents a central tenet of per-
forming randomized clinical superiority trials. Inten-
tion-to-treat refers to the axiom that patients enrolled
in a randomized clinical trial are analyzed according
to their initial arm assignment, regardless whether or
not they received the assigned treatment. It is well
known that some patients cross over from the as-
signed treatment arm to the other arm. In a conven-
tional superiority trial, an intention-to-treat analysis
usually decreases the diﬀerence in the outcome be-
tween the study groups and provides a conservative
approach to analysis by shifting results towards the
null hypothesis (the hypothesis of no diﬀerence).
Similarly, in a non-inferiority trial an intention-to-
treat analysis may decrease observed diﬀerences be-
tween the compared arms. This will, however, bias the
results towards the alternative hypothesis. Therefore,
we share the opinion that a non-inferiority trial
should be evaluated both by ‘‘intention-to-treat’’ as
well as ‘‘per protocol’’ analyses.2,3 If non-inferiority is
found in both analyses, we can be reasonably certain
that both treatments are in fact similar if study design
and conduct were appropriate.
Bio-Creep
Bio-creep refers to the phenomenon that the eﬃ-
cacy of investigational treatment could degrade over
time as they are repeatedly compared to less eﬃca-
cious treatments.2 Although bio-creep is mostly used
in the context of drug studies, it may also occur in
surgical clinical trials. For instance, a standard sur-
gical procedure (A) with an efﬁcacy of 75% was
originally determined to be superior to an initial
procedure (0), which had an efﬁcacy rate of 55%. In a
non-inferiority trial, a new, less-invasive procedure
(B) was compared to the standard procedure (A) and
was found to be non-inferior with a delta less than
20% and efﬁcacy rates of 60% (procedure B) and 75%
(procedure A). Another investigational surgical pro-
cedure (C) was later found to be non-inferior to
procedure (B) with a delta less than 20% and efﬁcacy
rates of 45% (procedure C) and 60% (procedure B).
Thus, by these criteria, one could erroneously assume
procedure (C) = procedure (B) = standard proce-
dure (A), which was superior to the initial procedure
(0), when in fact the efﬁcacy of procedure C may be
worse than historically demonstrated for procedure
(0) (Fig. 1). This phenomenon is termed ‘‘biocreep’’
and underscores the cardinal importance of selecting
an appropriate comparator therapy and non-inferi-
ority margin for a non-inferiority trial.2
Ethical Considerations in Performing a
Non-Inferiority Trial
The unique design of non-inferiority trials also in-
volves particular human ethics considerations.28
Based upon the uncertainty principle, a patient should
only be entered into a clinical trial if it is unclear which
treatment might be more beneﬁcial for the patient.28,29
It is critically important to carefully select the inves-
tigational treatment and endpoints for a non-inferi-
ority trial. Since the null hypothesis in a non-
inferiority trial requires investigators to assume that
the investigational treatment is inferior to the standard
treatment, it has been suggested that this information
must be shared with potential subjects, possibly
affecting their willingness to participate in the trial.28
EXAMPLES OF NON-INFERIORITY TRIALS IN
SURGICAL ONCOLOGY
Example 1
A landmark study of a comparison between two
surgical therapies for colon cancer will serve us as a
FIG. 1. Biocreep in a non-inferiority trial. A = Standard surgical
procedure (efﬁcacy of 75%), originally superior to initial procedure
(0, efﬁcacy of 55%). B = New therapy (efﬁcacy 60%) non-inferior
compared to A with a delta less than 20%. Another therapy C
(efﬁcacy 45%) non-inferior to therapy B with a delta less than 20%.
Erroneous conclusion that C = B = A, which is superior to 0. In
fact, the efﬁcacy of therapy C is worse than 0 by a difference x.
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ﬁrst example of a non-inferiority trial in surgical
oncology:30,31 in this multicenter trial, 872 patients
with histologically proven adenocarcinoma of the
colon were randomized to undergo either open co-
lectomy or laparoscopic-assisted colectomy for colon
cancer. There is a growing body of evidence that
laparoscopic colon surgery is associated with better
cosmesis, reduced incidence of early infectious wound
complications as well as late incisional hernia for-
mations, decreased post-operative pain, shorter hos-
pital stay, and faster recovery.32–38
On the basis of all these advantages laparoscopic
colon surgery would seem preferable to open colec-
tomy. However, until recently, it was unknown
whether laparoscopic surgery was as good (non-
inferior) to open surgery with respect to disease-free
and overall survival. Thus, the aim of this trial was to
evaluate if disease-free and overall survival are
equivalent (non-inferior) after laparoscopic com-
pared to the conventional open approach. The trial
was designed with a power of 81% (type II error
probability: 19%) to declare that the laparoscopic
procedure is inferior if indeed it were associated with
at least a 23% increase (non-inferiority margin, delta)
of cancer recurrence. Alpha (type I error probability)
was set at 5%.
After a median follow-up of 4.4 years, both dis-
ease-free and overall survival were similar in both
arms, suggesting that the laparoscopic-assisted co-
lectomy is a viable alternative with respect to eﬃcacy
(disease-free and overall survival) while having sig-
niﬁcant advantages over the conventional approach.
Example 2
A multicenter randomized clinical trial in surgical
oncology serves as another excellent example of a
non-inferiority trial.39 This study enrolled patients
with cancer of the distal half of the stomach. Patients
were randomized to undergo either total gastrectomy
(arm 1) or subtotal gastrectomy (arm 2). The primary
endpoint of the study was overall survival at 5-year
follow-up.
This non-inferiority trial aimed at clearing a dec-
ade-long controversy whether to perform a total or
subtotal gastrectomy in patients with distal gastric
cancer. Previously, a single randomized controlled
trial addressed this relevant research question in
1989.40 However, this previous study was methodo-
logically suboptimal (e.g., underpowered trial, lack-
ing control for prognostic variables). A total
gastrectomy may reduce the likelihood of recurrence
at the proximal resection margin, and may eliminate
the risk of developing a metachronous carcinoma in
the gastric remnant, suggesting a superiority in terms
of oncologic outcome. However, former non-ran-
domized studies did not show a better overall survival
in patients undergoing total gastrectomy compared to
those having a subtotal gastrectomy.41–44 Further-
more, it is well known that a total gastrectomy, which
requires an esophageal anastomosis, is the more
extensive operation and may be associated with an
increased morbidity, nutritional deﬁciencies, a lack-
ing preservation of physiologic functions of the gas-
tric remnant, and a reduced quality of life.45–47
Therefore, it would be of great clinical and poten-
tially economic beneﬁt if the more extensive total
gastrectomy could be replaced by a less traumatic
procedure, such as the distal gastrectomy in patients
with distal gastric cancer. Hence, a non-inferiority
trial was designed to compare 5-year overall survival
rates between patients undergoing total and subtotal
gastrectomy. Total gastrectomy was taken as a ref-
erence treatment, with an expected 5-year survival of
50%. The null hypotheses (H0) stated that the 5-year
survival for subtotal gastrectomy was 40% or less.
Conversely, the alternative hypothesis (Ha) stated
equivalent 5-year overall survival rates for total and
subtotal gastrectomies, with a non-inferiority margin
of 10%, a type I error (a) probability set at 0.05, and a
type II error (b) probability set at 0.2. Power calcu-
lations based on these assumptions resulted in a total
sample size of 600 patients. A total of 618 patients
were recruited, hence this trial was adequately pow-
ered. The estimated 5-year overall survival was 62.4%
in the total gastrectomy group and 65.3% in the
subtotal gastrectomy group. Therefore, the null
hypothesis was rejected and the alternative hypothe-
sis of equivalence of both treatment options was ac-
cepted. This non-inferiority trial considerably
contributed to our current surgical practice of per-
forming subtotal gastrectomy in patients with distal
gastric cancer, and helped to improve the post-oper-
ative quality of life for many of these patients.
CONCLUSIONS
The non-inferiority study in surgical oncology is a
unique research tool to conduct a clinical trial dem-
onstrating non-inferiority for investigational treat-
ments. This particular study design can provide
evidence that the investigational treatment is as eﬃ-
cacious as the standard treatment with respect to the
primary endpoint (e.g., overall survival), yet has fewer
side eﬀects, is less expensive, easier to administrate, or
NON-INFERIORITY TRIALS IN SURGICAL ONCOLOGY 1537
Ann. Surg. Oncol. Vol. 14, No. 5, 2007
is associated with improved post-operative quality of
life. However, the design and study conduct of non-
inferiority trials is associated with particular chal-
lenges and caveats. Particular attention to rigorous
methodology must be paid when planning, perform-
ing, or interpreting results of a non-inferiority trial.
We hope that the present overview clariﬁes some of
the most important aspects of non-inferiority trials
and helps the surgical oncologist in the interpretation
and implementation of their results.
QUALITY OF A NON-INFERIORITY TRIAL—A
CHECKLIST FOR THE SURGEON
 Is the study designed as a non-inferiority trial?
Remember: superiority trials that fail to reach
statistical signiﬁcance do not prove equivalence.
 Is the clinical effectiveness of the standard treatment
well established (assay sensitivity)? Remember: the
standard therapy in a non-inferiority trial must
perform as expected from previous clinical trials.
 Are type I error (alpha, false positive) and type II
error (beta, false negative) stated in the Method
section?
 Is a non-inferiority margin (delta) deﬁned in the
Method section?
 Is there a sample size calculation based on pre-stated
alpha, beta, and non-inferiority margin (delta)?
 Is the chosen non-inferiority margin smaller than
the least clinically meaningful difference?Would the
investigational treatment be acceptable if its efﬁcacy
was within the boundaries of the chosen delta?
 Does the study reach its target accrual? Is there a
considerable gap between computed sample size
and enrolled number of patients?
 Was the data analysis performed according to the
intention-to-treat principle or is it a per protocol
analysis? Remember that both evaluations are
important in a non-inferiority trial and should
result in similar conclusions for robust evidence of
equivalence.
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